3
|
Chepurny OG, Holz GG, Roe MW, Leech CA. GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion. Mol Endocrinol 2016; 30:614-29. [PMID: 27082897 DOI: 10.1210/me.2015-1306] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
GPR119 is a G protein-coupled receptor expressed on intestinal L cells that synthesize and secrete the blood glucose-lowering hormone glucagon-like peptide-1 (GLP-1). GPR119 agonists stimulate the release of GLP-1 from L cells, and for this reason there is interest in their potential use as a new treatment for type 2 diabetes mellitus. AS1269574 is one such GPR119 agonist, and it is the prototype of a series of 2,4,6 trisubstituted pyrimidines that exert positive glucoregulatory actions in mice. Here we report the unexpected finding that AS1269574 stimulates GLP-1 release from the STC-1 intestinal cell line by directly promoting Ca(2+) influx through transient receptor potential ankyrin 1 (TRPA1) cation channels. These GPR119-independent actions of AS1269574 are inhibited by TRPA1 channel blockers (AP-18, A967079, HC030031) and are not secondary to intracellular Ca(2+) release or cAMP production. Patch clamp studies reveal that AS1269574 activates an outwardly rectifying membrane current with properties expected of TRPA1 channels. However, the TRPA1 channel-mediated action of AS1269574 to increase intracellular free calcium concentration is not replicated by GPR119 agonists (AR231453, oleoylethanolamide) unrelated in structure to AS1269574. Using human embryonic kidney-293 cells expressing recombinant rat TRPA1 channels but not GPR119, direct TRPA1 channel activating properties of AS1269574 are validated. Because we find that AS1269574 also acts in a conventional GPR119-mediated manner to stimulate proglucagon gene promoter activity in the GLUTag intestinal L cell line, new findings reported here reveal the surprising capacity of AS1269574 to act as a dual agonist at two molecular targets (GPR119/TRPA1) important to the control of L-cell function and type 2 diabetes mellitus drug discovery research.
Collapse
Affiliation(s)
- Oleg G Chepurny
- Departments of Medicine (O.G.C., G.G.H., M.W.R., C.A.L.), Pharmacology (G.G.H.), and Cell and Developmental Biology (M.W.R.), State University of New York, and Upstate Medical University, Syracuse, New York 13210
| | - George G Holz
- Departments of Medicine (O.G.C., G.G.H., M.W.R., C.A.L.), Pharmacology (G.G.H.), and Cell and Developmental Biology (M.W.R.), State University of New York, and Upstate Medical University, Syracuse, New York 13210
| | - Michael W Roe
- Departments of Medicine (O.G.C., G.G.H., M.W.R., C.A.L.), Pharmacology (G.G.H.), and Cell and Developmental Biology (M.W.R.), State University of New York, and Upstate Medical University, Syracuse, New York 13210
| | - Colin A Leech
- Departments of Medicine (O.G.C., G.G.H., M.W.R., C.A.L.), Pharmacology (G.G.H.), and Cell and Developmental Biology (M.W.R.), State University of New York, and Upstate Medical University, Syracuse, New York 13210
| |
Collapse
|
4
|
Ritter K, Buning C, Halland N, Pöverlein C, Schwink L. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges. J Med Chem 2015; 59:3579-92. [PMID: 26512410 DOI: 10.1021/acs.jmedchem.5b01198] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
In this Perspective, recent advances and challenges in the development of GPR119 agonists as new oral antidiabetic drugs will be discussed. Such agonists are expected to exhibit a low risk to induce hypoglycemia as well as to have a beneficial impact on body weight. Many pharmaceutical companies have been active in the search for GPR119 agonists, making it a highly competitive area in the industrial environment. Several GPR119 agonists have been entered into clinical studies, but many have failed either in phase I or II and none has progressed beyond phase II. Herein we describe the strategies chosen by the different medicinal chemistry teams in academia and the pharmaceutical industry to improve potency, physicochemical properties, pharmacokinetics, and the safety profile of GPR119 agonists in the discovery phase in order to improve the odds for successful development.
Collapse
Affiliation(s)
- Kurt Ritter
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Christian Buning
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Nis Halland
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Christoph Pöverlein
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Lothar Schwink
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| |
Collapse
|
5
|
Scott JS, Bowker SS, Brocklehurst KJ, Brown HS, Clarke DS, Easter A, Ertan A, Goldberg K, Hudson JA, Kavanagh S, Laber D, Leach AG, MacFaul PA, Martin EA, McKerrecher D, Schofield P, Svensson PH, Teague J. Circumventing Seizure Activity in a Series of G Protein Coupled Receptor 119 (GPR119) Agonists. J Med Chem 2014; 57:8984-98. [DOI: 10.1021/jm5011012] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- James S. Scott
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Suzanne S. Bowker
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Katy J. Brocklehurst
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Hayley S. Brown
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - David S. Clarke
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Alison Easter
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Anne Ertan
- Pharmaceutical Development, AstraZeneca R&D, S-151 85 Södertälje, Sweden
| | - Kristin Goldberg
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Julian A. Hudson
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Stefan Kavanagh
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - David Laber
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Andrew G. Leach
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Philip A. MacFaul
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Elizabeth A. Martin
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Darren McKerrecher
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Paul Schofield
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Per H. Svensson
- Pharmaceutical Development, AstraZeneca R&D, S-151 85 Södertälje, Sweden
| | - Joanne Teague
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| |
Collapse
|
10
|
Darout E, Robinson RP, McClure KF, Corbett M, Li B, Shavnya A, Andrews MP, Jones CS, Li Q, Minich ML, Mascitti V, Guimarães CRW, Munchhof MJ, Bahnck KB, Cai C, Price DA, Liras S, Bonin PD, Cornelius P, Wang R, Bagdasarian V, Sobota CP, Hornby S, Masterson VM, Joseph RM, Kalgutkar AS, Chen Y. Design and Synthesis of Diazatricyclodecane Agonists of the G-Protein-Coupled Receptor 119. J Med Chem 2012; 56:301-19. [DOI: 10.1021/jm301626p] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Etzer Darout
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Ralph P. Robinson
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Kim F. McClure
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Matthew Corbett
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Bryan Li
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Andrei Shavnya
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Melissa P. Andrews
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Christopher S. Jones
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Qifang, Li
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Martha L. Minich
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Vincent Mascitti
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Cristiano R. W. Guimarães
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Michael J. Munchhof
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Kevin B. Bahnck
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Cuiman Cai
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - David A. Price
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Spiros Liras
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Paul D. Bonin
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Peter Cornelius
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Ruduan Wang
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Victoria Bagdasarian
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Colleen P. Sobota
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Sam Hornby
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Victoria M. Masterson
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Reena M. Joseph
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 620 Memorial
Drive, Cambridge, Massachusetts 02139, United States
| | - Yue Chen
- Departments of Medicinal Chemistry,
Discovery Biology, Drug Metabolism, and Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|